gnipst bulletin 45.4

29-05-2015

GGGNNNIIIPPPSSSTTT BBBUUULLLLLLEEETTTIIINNN 22200011155529th May, 2015 Volume No.: 45 Issue No.: 04

Vision

TO REACH THE PINNACLE OF GLORY AS A CENTRE OF EXCELLENCE IN THE FIELD OF PHARMACEUTICAL AND BIOLOGICAL SCIENCES BY KNOWLEDGE

BASED LEARNING AND PRACTICE

Contents Message from PRINCIPAL Editorial board Historical article News Update Knowledge based Article Disease Related Breaking

News Upcoming Events Drugs Update Campus News Students Section Editors Note Archive

GNIPST Photo Gallery For your comments/contribution OR For Back-Issues, mailto:[email protected]

GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY W e bs i t e : ht t p: / / gni ps t. a c. i n

29-05-2015

MESSAGE FROM PRINCIPAL

"It can happen. It does happen. But it can't happen if you quit." Lauren Dane.

We are what we repeatedly do. Excellence then is not an act, but a habit. Aristotle

It gives me immense pleasure to pen a few words for our e-bulletin. At the onset I would like to thank the last years editors and congratulate the newly selected editors for the current year.

Our first consideration is always in the best interest of the students. Our goal is to promote academic excellence and continuous improvement.

I believe that excellence in education is aided by creating a learning environment in which all learners are supported in maximizing their potential and talents. Education needs to focus on personalized learning and instruction, while promoting an education system that is impartial, universally accessible, and meeting the needs of all students.

It is of paramount importance that our learners have sufficient motivation and encouragement in order to achieve their aims. We are all very proud of you, our students, and your accomplishments and look forward to watching as you put your mark on the profession in the years ahead.

The call of the time is to progress, not merely to move ahead. Our progressive Management is looking forward and wants our Institute to flourish as a Post Graduate Institute of Excellence. Steps are taken in this direction and fruits of these efforts will be received by our students in the near future. Our Teachers are committed and dedicated for the development of the institution by imparting their knowledge and play the role of facilitator as well as role model to our students.

The Pharmacy profession is thriving with a multitude of possibilities, opportunities and positive challenges. At Guru Nanak Institute of Pharmaceutical Science and Technology, our focus is on holistic needs of our students.

I am confident that the students of GNIPST will recognize all the possibilities, take full advantage of the opportunities and meet the challenges with purpose and determination.

Excellence in Education is not a final destination, it is a continuous walk. I welcome you to join us on this path.

My best wishes to all.

Dr. A. Sengupta

Click here to go at the top

1

29-05-2015

EDITORIAL BOARD

CHIEF EDITOR DR. ABHIJIT SENGUPTA EDITOR MS. JEENATARA BEGUM ASSOCIATE EDITOR MR. DIPANJAN MANDAL

HISTORICAL ARTICLE Pharmaceutical Manufacturing Comes of Age: Pharmaceutical manufacturing as an industry apart from retail Pharmacy had its beginnings about 1600; really got under way in the middle 1700's. It developed first in Germany, then in England and in France. In America, it was the child of wars - born in the Revolution; grew rapidly during and following the Civil War; became independent of Europe during World War I; came of age during and following World War II. Utilizing latest technical advances from every branch of science, manufacturing Pharmacy economically develops and produces the latest and greatest in drugs in immense quantities, so that everywhere physicians may prescribe them and pharmacists dispense them for the benefit of all mankind.

NEWS UPDATE Smokers and those exposed to passive smoke

require more anesthetic and painkiller during operations: (29th May,2015) New research shows that both smokers and those exposed to passive smoke require more anesthetic and painkillers to reach the same level of anesthesia as non-smokers.


2

29-05-2015

Before an operation, low blood pressure rather than high is a risk factor for death: (29th May,2015) New research suggests that, before an operation, low blood pressure rather than high blood pressure is an independent risk factor for death.

Hypothermia occurs during surgery in around half of patients: (29th May,2015) A study shows that hypothermia occurs in around half of patients undergoing surgery, despite national guidelines for its prevention.

Blood pressure medications can lead to increased risk of stroke: (29th May,2015) The importance of preventing hypertension is reinforced by a study showing anti-hypertension medicines can increase stroke risk by 248 percent, according to new research.

Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy: (29th May,2015) A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences--and so preventing mutations--are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability.


3

29-05-2015

Altered pain processing in patients with cognitive impairment: (29th May,2015) People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a new research review.

Less-invasive method for kidney diagnostics: (29th May,2015) Researchers have identified a new, less-invasive method to provide diagnostic information on kidney disease and its severity.

Alzheimer's culprit causes memory loss even before brain degeneration: (29th May,2015) A brain protein believed to be a key component in the progress of dementia can cause memory loss in healthy brains even before physical signs of degeneration appear, according to new research.

Rewriting the book on chemo-resistant cancers with a DNA library: (29th May,2015) Researcher are finding out why ovarian cancer is resistant to certain types of chemo and hope to eventually identify a different drug target.

Biomarker analysis reveals several potential treatment targets in subtype of anal cancer: (29th May,2015) A multiplatform biomarker analysis of squamous cell anal carcinoma samples has revealed several actionable targets. For detail mail to editor


4

29-05-2015

KNOWLEDGE BASED ARTICLE Lassa Fever

Description: An extremely virulent, often fatal, Old-World, viral hemorrhagic illness. Lassa fever, an arenavirus, is an enveloped, single-stranded, bisegmented RNA virus. As with other arenaviruses, Lassa virus does not have a conventional negative-strand coding arrangement. Lassa fever occurs more often in the dry season, rather than in the rainy season. It is the most commonly "exported" hemorrhagic fever; its victims carry the disease from Africa to the United States, to the United Kingdom, tp the Netherlands, Israel, and Japan. Lassa fever is named after the town (in the Yedseram River valley) in which the first cases were isolated in 1969, during a nosocomial outbreak at a local hospital. (A clinical description of Lassa fever was published in Sierra Leone over a decade earlier, but received little or no attention.) Location: Parts of West Africa, including Guinea, Sierra Leone, Nigeria, and Liberia. However, sporadic Lassa infections may have also occurred in Senegal and Mali. One host genus has been identified as spreading at least one Lassalike virus in central Africa. Vector: The rat species Mastomys, in particular, M. natalensis. This is a consistent host reservoir for the Lassa virus because of congenital neonatal infection, which results in rats with long-lasting and/or lifelong infection. Because of the mechanism of infection, there is no break in the natural chain from virus to host species. The rats themselves might show no symptoms of the disease, but they shed the virus freely in urine and droppings, and secrete the virus in their saliva. Because certain varieties of Mastomys often live in human homes, the virus is easily transmitted to humans. Transmission occurs via direct contact with rat urine, feces, and saliva; via contact with excretion- or secretion-infected materials; or via ingestion of excretion-contaminated food. Victims can also become infected


5

29-05-2015

via skin breaks, and via mucous membranes from aerosol transmission from dust-borne particles. In some areas, the rodents are used as a food source, thus providing additional exposure to the infected rat blood, as well as allowing ingestion of potentially contaminated meat. Laboratory workers become infected usually from contact with rodent saliva. Unlike other arenaviruses, Lassa virus can be fairly easily transmitted from human to human. Humans can contract the disease from other humans via aerosol transmission (coughing), or from direct contact with infected human blood, urine, or semen. Lassa virus has been isolated from semen 6 weeks after acute illness; the virus can be transmitted to sexual partners by convalescent men. Mechanism: The virus enters the human body through the bloodstream, lymph vessels, respiratory tract, and/or digestive tract. It then multiplies in cells of the reticuloendothelial system. Virus replication in the reticuloendothelial cells causes capillary lesions. These capillary lesions lead to erythrocyte and platelet loss, with mild to moderate thrombocytopenia and a tendency toward bleeding. Capillary lesions also cause increased vascular permeability and hemorrhage in various organs, such as the stomach, small intestine, kidneys, lungs, and brain. Incubation Period: Usually about 10 days. Can range from 1-24 days. Most patients display symptoms for 4 to 5 days before seeking hospital treatment. Symptoms: Gradual onset of fever and malaise. Increased fever (which can last 2-3 weeks) and myalgia, with severe prostration, accompanied by involvement of specific organs and serosa. Patients frequently present with pain behind the sternum and with coughing. Additional common symptoms include: abdominal pain, nausea and vomiting, diarrhea, or constipation; also: conjunctivitis, pharyngitis (inflammation of mucous membranes and the


6

29-05-2015

underlying parts of the pharynx), increased vascular permeability (such as pleural effusions), and proteinuria (protein in the urine). About 10-30% of patients present with facial and neck swelling. Approximately 2/3 of patients present with sore throat, usually accompanied by objective inflammatory or exudative (oozing) pharyngitis. Some patients experience adult respiratory distress syndrome. Skin rashes and jaundice are rare. Some patients experience bleeding from the gums. In addition, capillary lesions cause hemorrhaging in the stomach, small intestine, kidneys, lungs, and brain. Less than 1/3 of patients present with bleeding; however, bleeding is a predictor of a significantly higher risk of death. In severe cases of Lassa fever, shock and vascular collapse occur, followed by death. Research suggests that the shock results from platelet and endothelial dysfunction, which cause hemorrhage and allow fluid to leak into the intravascular system. Patients who will survive begin to defervesce 2-3 weeks after onset of the disease. In contrast, patients who are at the greatest risk of dying usually develop shock, clouded mental status, agitation, rales, pleural effusion, and sometimes grand mal seizures. The four symptoms associated with a 2.5-fold or higher risk of mortality are: vomiting, sore throat, tachypnea (rapid breathing), or bleeding. During convalescence, although the virus may no longer be found in the blood, pericarditis can occur, especially in males. The following conditions may also occur during convalescence: aseptic meningitis, encephalitis, global encephalopathy with seizures, cerebellar ataxia (uncommon), and deafness (common). Temporary or permanent deafness in one or both ears occurs in 29% of Lassa fever patients. Experiments on guinea pigs have shown that Lassa virus can manifest differently, with significantly varying symptoms. It is suspected that subtle genetic changes in tissue-specific variants of the disease create the differences in disease manifestation.


7

29-05-2015

Diagnosis: Lassa virus can be diagnosed in three ways: 1. Isolating the virus from blood, urine, or throat washings. 2. Demonstrating the presence of immunoglobuline M (IgM)

antibody to Lassa virus. 3. Showing a fourfold rise in titer of IgG antibody between

acute- and convalescent-phase serum. The virus can be isolated from the blood or serum during the febrile phase of the disease, up to 2 weeks postonset. Antibody can be detected by CF, IFA, or ELISA. In severe cases, patients can die before the appearance of antibodies. Other laboratory results:

Leukocyte count can be low, normal, or moderately elevated. Platelet counts are usually normal, but might be slightly low. AST (SGOT) and ALT (SGPT) are usually elevated (10x

normal). Chest x-rays are usually normal, but may show pleural

effusions or basilar pneumonitis. Albuminaturia (excessive amounts of albumin proteins in the

urine) is common. ECGs are usually abnormal.

Initial possible diagnoses of the Lassa-infected patient may include malaria, shigellosis, and typhoid. Mortality Rates: Prognosis for Lassa patients has a direct correlation to levels of viremia. However, prognosis does not correlate with the patient's development of IgM or IgG antibodies. The antibodies do not seem to neutralize the Lassa virus. The mortality rates for Lassa virus are typically estimated at 15% to 20%. Some studies estimate mortality as high as 45%. One survey of Lassa infection vs. mortality rates indicates that less than 1% of all Lassa-virus infections in West Africa will eventually result in fatal disease. The mortality rates for Lassa appear to be much higher in people of non-African stock. Lassa virus also causes high fetal mortality and high mortality in pregnant women. The mortality rate is 92% for fetuses in early


8

29-05-2015

pregnancy, 75% for fetuses in the third trimester, and 100% in the neonatal period for full-term babies. High concentrations of the virus have been found in both fetal tissue and in the placenta. It is suspected that maternal T cells cannot attack the concentrations of virus in the placenta because placental cells cannot express class I or class II MHC antigens. The mortality rate for gravid women is 7% in the first two trimesters, 30% in the last trimester, and 50% for pregnant women who delivered within 1 month. In contrast, the general mortality rate for nonpregnant women only is 13%. Treatment: For adults, ribavirin: 2-gm loading dose, followed by 1 gm every 6 hours for 4 days; followed by 0.5 gm every 8 hours for 6 days. There is no treatment for the deafness (which resembles idiopathic nerve disease) associated with Lassa fever. Antibiotics may also be administered to patients to ward off or treat secondary and/or opportunistic bacterial infections. Severely ill patients may receive treatment before the diganosis is confirmed. Currently, there is no effective prophylactic treatment for Lassa fever. However, some sources recommend prophylactic doses of Ribavirin for people coming in high-risk contact with viremic patients. Outbreaks and History of Infection: Lassa fever was first recognized in 1969 in Lassa, Nigeria. Subsequent outbreaks occurred in Nigeria, Liberia, and Sierra Leone. In some parts of Sierra Leone and Liberia, 10% to 16% of all patients admitted to hospitals have Lassa fever. Some Lassa fever cases have been "imported" into the U.S. and U.K. through viremic travelers who acquired the disease elsewhere. A few notes on outbreaks: - 1969, northern Nigeria - first recognized outbreak of the disease. - 1970 to present, Liberia. Most cases were hospital workers who acquired the disease in the hospital from the index patient. - 1970 to present, Sierra Leone. It is estimated that 6% of all residents in the initial endemic area have antibodies to Lassa Fever,


9

29-05-2015

even though only 0.2% were recognized as clinically ill. - Estimated 100,000-300,000 infections per year in West Africa. About 2/3 of all reported cases are women, but this might be a result of exposure, rather than a tendency toward greater susceptibility in women to the disease. Vaccine: No vaccine is currently available. However, the most promising approach to developing a vaccine appears to be via vaccinia-vectored Lassa genes. These have been protective in both guinea pigs and nonhuman primates.

Jeenatara Begum Assistant Professor

GNIPST

DISEASE RELATED BREAKING NEWS Lassa Fever United States of America: (28th

May, 2015) On 25 May, PAHO/WHO was informed that the United States Center for Disease Control and prevention (CDC) and the New Jersey Department of Health had confirmed a fatal case of Lassa fever. The case was diagnosed on 25 May in a person returning to the U.S. from Liberia. Read more

UPCOMING EVENTS 61st IPSF World Congress sponsored by Indian Pharmaceutical

Association (IPA) at Marriott Hotel, Hyderabad, India is going to on 30th July to 9th August, 2015.


10

29-05-2015

DRUGS UPDATES FDA Approves Xifaxan (rifaximin) for the

Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) : (27th May, 2015) Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan 550 mg for the treatment of IBS-D in adults. The FDA approval of Xifaxan 550 mg is based on data from three phase 3 studies, TARGET 1, TARGET 2 and TARGET 3. Xifaxan 550 mg was studied in over 3,000 patients and demonstrated the efficacy and safety of repeat treatment following completion of a two-week course of treatment. A full course of Xifaxan 550 mg for IBS-D is available in a convenient 2 week pack of 42 pills. Read more

CAMPUS NEWSFAREWELL PROGRAMME:

On 15th May 2015 GNIPST clebrated the farewell programme Sesh Chithi for the final year students of M.Pharm, M.Sc, B.Pharm, B.Sc and BHM.

JIS SAMMAN 2015 On 11th May, 2015 GNIPST attended the JIS SAMMAN 2015.

JIS SAMMAN Awards: Best College (Non Engineering):

GNIPST Best Principal:

Dr (Prof.) Avijit Sengupta Best HOD:

Mr. Jaydip Ray Best Faculty:

Mr. Debabrata Ghoshdastidar (Pharmacy)


11

29-05-2015

Dr. Swati Chakraborty (Life Sciences) Best faculty since inception:

Mr. Jaydip Ray Best Office Staff:

Ms. Jaya Banerjee Best technical Assistant:

Mr. Somnath Majhi College Blue:

Avik Paul Highest DGPA of 2014:

B.Pharm:Purbali Chakraborty (4th year) Diksha Kumari (3rd year) Aishika Dutta (2nd year) Sampita Paul (1st year) M.Pharm: Aritra Mukherjee (Pharmaceutical Chemistry) Mounomukhar Bhattacharya (Pharmacology) B.Sc (Biotechnology): Papiya Saha (3rd year) Shomasree Das (2nd year) Ayanita Basak (1st year) B.Sc (Microbiology): Bonhisikha Chatterjee (3rd year) Riaz Hossain (2nd year) Soumi Chowdhury (1st year) BHM: Bishal Roy (3rd year) Shreyabhanja Chowdhury (2nd year) Recitation:

Udita Majumder Debate:

Srijita Roy Poushali Ganguly


12

29-05-2015

Band: Syantan Ghoswami Anurag Ghosh Atanu Mondal Arka Khamaru Ritobroto Paul Abhirup Dasgupta

Fashion: Md. Nadeem Shah Koustav Sarkar Shaksar Saha Avirup Dasgupta Ranit Kundu Namrata Ganguly Shreyasee Mitra Chandrika Saha Debopriya Chatterjee Riya Taran

Innovative Modeling: Ankit Chowdhury Kartik Koley Mudasar Manna Dipan Chaterjee Abhishek Singh Kaustav Pal Manojit Dutta SPIRIT JIS 2015

On 03th to 05th April, 2015 JIS organised SPIRIT JIS 2015. GPAT 2015 Result:

The following B.Pharm. final year students have qualified, GPAT-2015. We congratulate them all. Diksha Kumari Rupanjay Bhattacharya Avik Paul


13

29-05-2015

Xtasy 2015: GNIPST is going to organize the Tech Fest Xtasy 2015 from 30th March, 2015 to 1st April, 2015.

FINISHING SCHOOL TRAINING PROGRAMME: The FINISHING SCHOOL TRAINING PROGRAMME is going to organize by the Entrepreneurship Development Cell and Training & Placement Cell, GNIPST in collaboration with Indian Pharmacy Graduates Association (IPGA), Bengal Branch from 21st February to 11th April, 2015 at GNIPST Auditorium. On 21

st February, 2015 the Finishing School Training Programme of

GNIPST was inaugurated by Sri Soumen Mukhopadhyay, Deputy Director, Drug Control Office, Goutam Kr. Sen, President, IPGA, Mr. Subroto Saha, Asst. Directorate, Drug Control Office, Mr. Ranendra Chakraborty, Sales Manager and Associate Director Dr. Reddys Laboratory. On 28th February, 2015 Dr. D. Roy, Former Deputy Drug Controller, Mr. Sujoy Chakraborty, divisional Therapy Manager, Cipla and Mr. Vikranjit Biswas, Senior Manager, Learning & Development, Cipla delivered their valuable lectures in the 2nd day FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 14th March, 2015 Mr. Milindra Bhattacharya, Senior Manager, QA & QC, Emami Ltd. and Mr. Joydev Bhoumik, Manager, Operation, Ranbaxy Laboratory Limited delivered their valuable lectures in the 3rd day FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 21st March, 2015 Mr. Tridib Neogi, Associate Vice-President (Quality Assurance), Albert David Ltd. delivered his valuable lectures in the 4th FINISHING SCHOOL TRAINING PROGRAMME of GNIPST. On 28th March, 2015 Dr. Gautam Chaterjee, an Alumni of Jadavpur University and presently associated with NIPER delivered his valuable lectures in the 5th FINISHING SCHOOL TRAINING PROGRAMME of GNIPST.


14

29-05-2015

On 11th April, 2015 the closing ceremony of the FINISHING SCHOOL TRAINING PROGRAMME was held in GNIPST Auditorium. JOBS:

All the students of Final Year B. Pharm and M. Pharm are hereby informed that an interview will be conducted on 23rd May, 2015 by Standard Pharmaceuticals Ltd. GSK for post: Production, QA, QC. All the students of Final Year B. Pharm and M. Pharm are hereby informed that an interview will be conducted by GSK for sales and marketing job. Details given below:

Date: 27.03.2015Time: 09:45 amVenue : GSK Consumer Healthcare Limited, Unit No. 208,

2nd Floor, Ecospace Campus B (3 B), New Town, Rajarhat, 24 Pgs (N). Kolkata-700156.

THYROCARE provisionally selected 15 students from JIS Group. Amongst these, 3 students of B. Sc (H) Biotechnology and M. Sc Biotechnology have been selected. Ipsita Mondal (M. Sc Biotechnology)Debriti Paul (M. Sc Biotechnology)Debopriya Chatterjee {B. Sc (H) Biotechnology}

The final year students of B.Pharm (31 students) and B.Sc (11 students) attended the pooled campus drive of Abbott India Ltd. on 10th March, 2015 at Jadavpur University. Among them 17 students have gone through to the final round of this pooled campus drive and short listed for final selection.

ACHIEVEMENT: Congratulations to Anurag Chanda, student of B.Pharm final year

who have got the 1st prize in poster presentation event in Prakriti 2015 at Department of Agricultural and Food engineering, IIT, Kharagpur.


15

29-05-2015

OTHERS: On 24th and 25th February, 2015 Swamiji of Gourio Mathwasdelivered some motivational lectuers in GNIPST.

The students of GNIPST participated in the 4th Sardar JodhSinghTrophy organised by NIT on 20th February, 2015. On 8th February, 2015 Gnipst celebrated the ReunionprogrammeReminiscence Reloaded 2015.

STUDENTS SECTION WHO CAN ANSWER FIRST????

Think outside the box is the tagline of whichcompany?

Answer of Previous Issues Questions: A) Human genome project

Identify

Answer of Previous Issues Image: Larry Page and Sergey Brin, founder of GOOGLE

Send your thoughts/Quiz/Puzzles/games/write-ups or any other contributions for Students Section& answers of this Section at [email protected]


16

29-05-2015

EDITORS NOTE

It is a great pleasure for me to publish the 4th issue of 45th Volume of GNIPST BULLETIN. All the followers of GNIPST BULLETIN are able to avail the bulletin through facebook account GNIPST bulletin I am very much thankful to all the GNIPST members and readers who are giving their valuable comments, encouragements and supports. I am also thankful to Dr. Abhijit Sengupta, Director of GNIPST for his valuable advice and encouragement. Special thanks to Dr. Prerona Saha, Mr. Debabrata Ghosh Dastidar and Mr. Soumya Bhattacharya for their kind co-operation and technical supports. Thank you Mr. Soumya Bhattacharya for the questionnaires of the student section. An important part of the improvement of the bulletin is the contribution of the readers. You are invited to send in your write ups, notes, critiques or any kind of contribution for the forthcoming special and regular issue.

ARCHIVE The general body meeting of APTI, Bengal Branch has been

conducted at GNIPST on 15th June, 2012. The program started witha nice presentation by Dr. Pulok Kr. Mukherjee, School of NaturalProducts, JU on the skill to write a good manuscript forpublication in impact journals. It was followed by nearly two hourlong discussion among more than thirty participants on differentaspects of pharmacy education. Five nonmember participantsapplied for membership on that very day.

GNIPST is now approved by AICTE and affiliated to WBUT forconducting the two years post graduate course (M.Pharm)in PHARMACOLOGY. The approved number of seat is 18.


17

29-05-2015

The number of seats in B.Pharm. has been increased from 60 to120.

AICTE has sanctioned a release of grant under ResearchPromotion Scheme (RPS) during the financial year 2012-13toGNIPST as per the details below:a. Beneficiary Institution: Guru Nanak Institution of PharmaceuticalScience & Technology.

b. Principal Investigator: Dr. LopamudraDutta.c. Grant-in-aid sanctioned:Rs. 16,25000/- only

d. Approved duration: 3 yearse. Title of the project: Screening and identification of potential

medicinal plant of Purulia & Bankura districts of West Bengal with respect to diseases such as diabetes, rheumatism, Jaundice, hypertension and developing biotechnological tools for enhancing bioactive molecules in these plants.

Activity Clubs of GNIPST: Name of Club Member Faculty SPORTS Mr. Debabrata GhoshDastidar LITERARY AND PAINTING Ms. Jeenatara Begum SCIENCE AND INNOVATIVE MODELLING

Mr. Samrat Bose

ECO Ms. Sumana Roy SOCIAL SERVICES Dr. Asis Bala PHOTOGRAPHY Ms. Sanchari Bhattacharya CULTURAL Ms. Priyanka Ray DEBATE AND EXTEMPORE Mr. Soumya Bhattacharya


18

Smokers and those exposed to passive smoke require more anesthetic and painkiller during operations: (29th May,2015)New research shows that both smokers and those exposed to passive smoke require more anesthetic and painkillers to reach the same level of anesthesia as non-smokers. Before an operation, low blood pressure rather than high is a risk factor for death: (29th May,2015)

New research suggests that, before an operation, low blood pressure rather than high blood pressure is an independent risk factor for death. Hypothermia occurs during surgery in around half of patients: (29th May,2015)

A study shows that hypothermia occurs in around half of patients undergoing surgery, despite national guidelines for its prevention. Blood pressure medications can lead to increased risk of stroke: (29th May,2015) Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy: (29th May,2015) Altered pain processing in patients with cognitive impairment: (29th May,2015) Less-invasive method for kidney diagnostics: (29th May,2015) Alzheimer's culprit causes memory loss even before brain degeneration: (29th May,2015) Rewriting the book on chemo-resistant cancers with a DNA library: (29th May,2015) Biomarker analysis reveals several potential treatment targets in subtype of anal cancer: (29th May,2015)

KNOWLEDGE BASED ARTICLELassa FeverDescription: An extremely virulent, often fatal, Old-World, viral hemorrhagic illness. Lassa fever, an arenavirus, is an enveloped, single-stranded, bisegmented RNA virus. As with other arenaviruses, Lassa virus does not have a conventional negative-... Lassa Fever United States of America: (28th May, 2015)On 25 May, PAHO/WHO was informed that the United States Center for Disease Control and prevention (CDC) and the New Jersey Department of Health had confirmed a fatal case of Lassa fever. The case was diagnosed on 25 May in a person returning to the U....Read more FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) : (27th May, 2015)Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan 550 mg for the treatment of ...Read more CAMPUS NEWS STUDENTS SECTION

gnipst bulletin 45.4

Documents

students of gnipst

centre of excellence

academic excellence

field of pharmaceutical

knowledge based learning

years editors

education system

editorial board chief